HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ronald Steis Selected Research

IDM 2101

9/2008Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ronald Steis Research Topics

Disease

1Inflammation (Inflammations)
08/2018
1Disease Progression
08/2018
1Anemia
08/2018
1Carcinogenesis
08/2018
1Breast Neoplasms (Breast Cancer)
08/2018
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2008
1Neoplasms (Cancer)
09/2008
1Multiple Myeloma
10/2006

Drug/Important Bio-Agent (IBA)

1Hormones (Hormone)IBA
08/2018
1Capecitabine (Xeloda)FDA Link
08/2018
1ruxolitinibIBA
08/2018
1Phosphotransferases (Kinase)IBA
08/2018
1C-Reactive ProteinIBA
08/2018
1IDM 2101IBA
09/2008
1EpitopesIBA
09/2008
1AntigensIBA
09/2008
1VaccinesIBA
09/2008
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
10/2006
1Melphalan (Alkeran)FDA LinkGeneric
10/2006
1Arsenic Trioxide (Trisenox)FDA Link
10/2006

Therapy/Procedure

2Therapeutics
08/2018 - 10/2006
1Drug Therapy (Chemotherapy)
08/2018
1Immunotherapy
09/2008
1MAC combination (MAC protocol)
10/2006